Collectivity of 0\u3csup\u3e+\u3c/sup\u3e States in \u3csup\u3e160\u3c/sup\u3eGd

Excited 0+ states in 160Gd have been examined with the (n,n′γ) reaction at incident neutron energies up to 2.8 MeV. Gamma-ray excitation functions and angular distribution measurements allow the confirmation of the existence of 0+ states at 1379.70 keV and 1558.30 keV, but we reject the assignments of additional previously suggested 0+ candidates. Limits on the level lifetimes of the observed 0+ states permit an evaluation of the collectivity of these states

Lifetime Measurements of Low-Spin Negative-Parity Levels in \u3csup\u3e160\u3c/sup\u3eGd

160Gd(n,n′γ) experiments were performed with accelerator-produced monoenergetic neutrons. Excitation functions at neutron energies from 1.5 to 2.8 MeV aided in the placement of γ rays in the level scheme and angular distributions at three neutron energies resulted in the determination of 28 excited-level lifetimes or limits in 160Gd, including the lifetimes of several negative-parity levels attributed to octupole vibrations

Studies of \u3csup\u3e54,56\u3c/sup\u3eFe Neutron Scattering Cross Sections

Elastic and inelastic neutron scattering differential cross sections and γ-ray production cross sections have been measured on 54,56Fe at several incident energies in the fast neutron region between 1.5 and 4.7 MeV. All measurements were completed at the University of Kentucky Accelerator Laboratory (UKAL) using a 7-MV Model CN Van de Graaff accelerator, along with the neutron production and neutron and γ-ray detection systems located there. The facilities at UKAL allow the investigation of both elastic and inelastic scattering with nearly mono-energetic incident neutrons. Time-of-flight techniques were used to detect the scattered neutrons for the differential cross section measurements. The measured cross sections are important for fission reactor applications and also for testing global model calculations such as those found at ENDF, since describing both the elastic and inelastic scattering is important for determining the direct and compound components of the scattering mechanism. The γ-ray production cross sections are used to determine cross sections to unresolved levels in the neutron scattering experiments. Results from our measurements and comparisons to model calculations are presented

C-Peptide Increases Na,K-ATPase Expression via PKC- and MAP Kinase-Dependent Activation of Transcription Factor ZEB in Human Renal Tubular Cells

Replacement of proinsulin C-peptide in type 1 diabetes ameliorates nerve and kidney dysfunction, conditions which are associated with a decrease in Na,K-ATPase activity. We determined the molecular mechanism by which long term exposure to C-peptide stimulates Na,K-ATPase expression and activity in primary human renal tubular cells (HRTC) in control and hyperglycemic conditions.HRTC were cultured from the outer cortex obtained from patients undergoing elective nephrectomy. Ouabain-sensitive rubidium ((86)Rb(+)) uptake and Na,K-ATPase activity were determined. Abundance of Na,K-ATPase was determined by Western blotting in intact cells or isolated basolateral membranes (BLM). DNA binding activity was determined by electrical mobility shift assay (EMSA). Culturing of HRTCs for 5 days with 1 nM, but not 10 nM of human C-peptide leads to increase in Na,K-ATPase α(1)-subunit protein expression, accompanied with increase in (86)Rb(+) uptake, both in normal- and hyperglycemic conditions. Na,K-ATPase α(1)-subunit expression and Na,K-ATPase activity were reduced in BLM isolated from cells cultured in presence of high glucose. Exposure to1 nM, but not 10 nM of C-peptide increased PKCε phosphorylation as well as phosphorylation and abundance of nuclear ERK1/2 regardless of glucose concentration. Exposure to 1 nM of C-peptide increased DNA binding activity of transcription factor ZEB (AREB6), concomitant with Na,K-ATPase α(1)-subunit mRNA expression. Effects of 1 nM C-peptide on Na,K-ATPase α(1)-subunit expression and/or ZEB DNA binding activity in HRTC were abolished by incubation with PKC or MEK1/2 inhibitors and ZEB siRNA silencing.Despite activation of ERK1/2 and PKC by hyperglycemia, a distinct pool of PKCs and ERK1/2 is involved in regulation of Na,K-ATPase expression and activity by C-peptide. Most likely C-peptide stimulates sodium pump expression via activation of ZEB, a transcription factor that has not been previously implicated in C-peptide-mediated signaling. Importantly, only physiological concentrations of C-peptide elicit this effect

Probing the low-lying level structure of 94Zr through β¯ decay

223-227Low-lying states of 94Zr are populated following b- decay of 94Y, and the emitted g rays from 94Zr are detected using the 8p spectrometer composed of 20 Compton-suppressed HPGe detectors. High- statistics coincidence data have been used for the placement of very weak decay branches in the level scheme. Combining the results of level lifetimes from a previous experiment and the precisely measured branching ratio values of the weak decay branches from the present experiment, it is possible to extract the B(E2) values for all the possible decay branches from a given level. These values are helpful for proper identification of the collective and non-collective states of 94Zr. The experimental findings have been compared with predictions from shell-model calculations with a limited valence space; however, these calculations are inadequate in reproducing all of the measured spectroscopic quantities

Microsecond Isomer at the N=20 Island of Shape Inversion Observed at FRIB

Excited-state spectroscopy from the first Facility for Rare Isotope Beams (FRIB) experiment is reported. A 24(2)-$\mu$s isomer was observed with the FRIB Decay Station initiator (FDSi) through a cascade of 224- and 401-keV $\gamma$ rays in coincidence with $^{32}\textrm{Na}$ nuclei. This is the only known microsecond isomer ($1{\text{ }\mu\text{s}}\leq T_{1/2} < 1\text{ ms}$) in the region. This nucleus is at the heart of the $N=20$ island of shape inversion and is at the crossroads of spherical shell-model, deformed shell-model, and ab initio theories. It can be represented as the coupling of a proton hole and neutron particle to $^{32}\textrm{Mg}$, $^{32}\textrm{Mg}+\pi^{-1} + \nu^{+1}$. This odd-odd coupling and isomer formation provides a sensitive measure of the underlying shape degrees of freedom of $^{32}\textrm{Mg}$, where the onset of spherical-to-deformed shape inversion begins with a low-lying deformed $2^+$ state at 885 keV and a low-lying shape-coexisting $0_2^+$ state at 1058 keV. We suggest two possible explanations for the 625-keV isomer in $^{32}$Na: a $6^-$ spherical shape isomer that decays by $E2$ or a $0^+$ deformed spin isomer that decays by $M2$. The present results and calculations are most consistent with the latter, indicating that the low-lying states are dominated by deformation.Comment: 7 pages, 5 figures, accepted by Physical Review Letter

Probing the low-lying level structure of 94Zr through β¯ decay

Low-lying states of 94Zr are populated following b- decay of 94Y, and the emitted g rays from 94Zr are detected using the 8p spectrometer composed of 20 Compton-suppressed HPGe detectors. High- statistics coincidence data have been used for the placement of very weak decay branches in the level scheme. Combining the results of level lifetimes from a previous experiment and the precisely measured branching ratio values of the weak decay branches from the present experiment, it is possible to extract the B(E2) values for all the possible decay branches from a given level. These values are helpful for proper identification of the collective and non-collective states of 94Zr. The experimental findings have been compared with predictions from shell-model calculations with a limited valence space; however, these calculations are inadequate in reproducing all of the measured spectroscopic quantities

Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017

Background Understanding the patterns of HIV/AIDS epidemics is crucial to tracking and monitoring the progress of prevention and control efforts in countries. We provide a comprehensive assessment of the levels and trends of HIV/AIDS incidence, prevalence, mortality, and coverage of antiretroviral therapy (ART) for 1980–2017 and forecast these estimates to 2030 for 195 countries and territories. Methods We determined a modelling strategy for each country on the basis of the availability and quality of data. For countries and territories with data from population-based seroprevalence surveys or antenatal care clinics, we estimated prevalence and incidence using an open-source version of the Estimation and Projection Package—a natural history model originally developed by the UNAIDS Reference Group on Estimates, Modelling, and Projections. For countries with cause-specific vital registration data, we corrected data for garbage coding (ie, deaths coded to an intermediate, immediate, or poorly defined cause) and HIV misclassification. We developed a process of cohort incidence bias adjustment to use information on survival and deaths recorded in vital registration to back-calculate HIV incidence. For countries without any representative data on HIV, we produced incidence estimates by pulling information from observed bias in the geographical region. We used a re-coded version of the Spectrum model (a cohort component model that uses rates of disease progression and HIV mortality on and off ART) to produce age-sex-specific incidence, prevalence, and mortality, and treatment coverage results for all countries, and forecast these measures to 2030 using Spectrum with inputs that were extended on the basis of past trends in treatment scale-up and new infections. Findings Global HIV mortality peaked in 2006 with 1·95 million deaths (95% uncertainty interval 1·87–2·04) and has since decreased to 0·95 million deaths (0·91–1·01) in 2017. New cases of HIV globally peaked in 1999 (3·16 million, 2·79–3·67) and since then have gradually decreased to 1·94 million (1·63–2·29) in 2017. These trends, along with ART scale-up, have globally resulted in increased prevalence, with 36·8 million (34·8–39·2) people living with HIV in 2017. Prevalence of HIV was highest in southern sub-Saharan Africa in 2017, and countries in the region had ART coverage ranging from 65·7% in Lesotho to 85·7% in eSwatini. Our forecasts showed that 54 countries will meet the UNAIDS target of 81% ART coverage by 2020 and 12 countries are on track to meet 90% ART coverage by 2030. Forecasted results estimate that few countries will meet the UNAIDS 2020 and 2030 mortality and incidence targets. Interpretation Despite progress in reducing HIV-related mortality over the past decade, slow decreases in incidence, combined with the current context of stagnated funding for related interventions, mean that many countries are not on track to reach the 2020 and 2030 global targets for reduction in incidence and mortality. With a growing population of people living with HIV, it will continue to be a major threat to public health for years to come. The pace of progress needs to be hastened by continuing to expand access to ART and increasing investments in proven HIV prevention initiatives that can be scaled up to have population-level impact